Skip to main content

Signifor LAR FDA Approval History

FDA Approved: Yes (First approved December 15, 2014)
Brand name: Signifor LAR
Generic name: pasireotide
Dosage form: for Injectable Suspension
Company: Novartis Pharmaceuticals Corporation
Treatment for: Acromegaly

Signifor LAR (pasireotide) is a long acting a somatostatin analog formulation for the treatment of patients with acromegaly.

Development timeline for Signifor LAR

Dec 16, 2014Approval Novartis Gains FDA Approval for Signifor LAR to Treat Patients with Acromegaly

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.